Skip to main content
SpringerLink
Log in

Normal CYP3A activity during arsenic trioxide therapy

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Buchner T, Dohner H, Burnett AK, Lo-Coco F (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875–1891

    Article  PubMed  CAS  Google Scholar 

  2. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lubbert M, Hanel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Dohner K, Sauer M, Ganser A, Amadori S, Mandelli F, Dohner H, Ehninger G, Schlenk RF, Platzbecker U, Gruppo Italiano Malattie Ematologiche dA, German-Austrian Acute Myeloid Leukemia Study G, Study Alliance L (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111–121

    Article  PubMed  CAS  Google Scholar 

  3. Gruppo Italiano Malattie EMatologiche dell’Adulto (2007) A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagnosed, non high-risk acute promyelocytic leukemia. http://clinicaltrials.gov/show/NCT00482833. Accessed 21 Mar 2014

  4. Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE (2013) A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther 93:564–571

    Article  PubMed  CAS  Google Scholar 

  5. Noreault TL, Kostrubsky VE, Wood SG, Nichols RC, Strom SC, Trask HW, Wrighton SA, Evans RM, Jacobs JM, Sinclair PR, Sinclair JF (2005) Arsenite decreases CYP3A4 and RXRalpha in primary human hepatocytes. Drug Metab Dispos 33:993–1003

    Article  PubMed  CAS  Google Scholar 

  6. Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G (2011) Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther 90:666–673

    Article  PubMed  CAS  Google Scholar 

  7. Katzenmaier S, Markert C, Mikus G (2010) Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam. Eur J Clin Pharmacol 66:1137–1141

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Monika Mauer for technical support during analytical procedures.

Conflict of interest

No conflicts of interest are declared by any of the authors.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany

    Nelly Siller, Nicolas Hohmann & Gerd Mikus

  2. Department of Internal Medicine V: Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany

    Gerlinde Egerer & Tilman Bochtler

Authors
  1. Nelly Siller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerlinde Egerer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tilman Bochtler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicolas Hohmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerd Mikus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerd Mikus.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Siller, N., Egerer, G., Bochtler, T. et al. Normal CYP3A activity during arsenic trioxide therapy. Ann Hematol 93, 1941–1942 (2014). https://doi.org/10.1007/s00277-014-2076-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2076-2

Keywords

Search

Navigation